西格列汀联合二甲双胍治疗新诊断2型糖尿病伴非酒精性脂肪肝的疗效观察被引量：13

下载PDF

导出

摘要目的观察西格列汀联合二甲双胍治疗新诊断2型糖尿病(T2DM)伴非酒精性脂肪性肝病(NAFLD)的临床疗效。方法收集新诊断T2DM合并NAFLD患者100例,采用随机数字表法将其分为观察组与对照组,各50例,两组均进行相关健康教育、饮食及运动治疗,观察组给予二甲双胍联合西格列汀口服,对照组给予二甲双胍口服,均治疗6个月,然后对两组治疗前后糖脂代谢相关指标、肝功能相关指标、肝脏B超及不良反应发生率进行比较。结果治疗后,两组糖代谢指标、肝功能相关指标及脂肪肝疗效差异均有统计学意义(均P<0.05),两组不良反应发生率差异无统计学意义(P>0.05)。结论西格列汀联合二甲双胍治疗新诊断T2DM合并NAFLD安全有效,且不增加不良反应发生率。

作者刘香兰胡朝晖刘加和

机构地区衢州市人民医院

出处《现代实用医学》 2016年第7期894-895,共2页 Modern Practical Medicine

关键词糖尿病 2型脂肪肝西格列汀二甲双胍

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献7

1Abdelaziz R, Elbasel M, Esmat S, et al. Tissueinhibitors o f metalloproteinase-1 and 2and obesity related non-alcoholic fatty Kverdisease: is there a relationship]. Digestion,2015,92(3): 130-137.
2Chai SY, Pan XY, Song KX, et al. Differentialpatterns o f insulin secretion and sensitivityin patients with type 2 diabetes mellitusand nonalcohoKc fatty liver disease versuspatients with type 2 diabetes mellitus alone[J]. Lipids Health Dis, 2014,13: 7.
3董春萍,吴贵福,李晓燕,何岚,高珊,李小凤.2型糖尿病合并非酒精性脂肪肝患者丙氨酸氨基转移酶水平与颈动脉粥样硬化的相关性[J].西安交通大学学报（医学版）,2013,34(4):512-515. 被引量：14
4张守清.二甲双胍联合谷胱甘肽治疗2型糖尿病合并非酒精性脂肪肝49例效果分析[J].医学理论与实践,2014,27(12):1589-1590. 被引量：4
5Itou M, Kawaguchi T, Taniguchi E, et al.Dipeptidyl peptidase IV inhibitor improvesinsulin resistance and steatosis in a refractorynonalcoholic fatty liver disease patient:a ease report [J]. Gastroenterology,2012,6(2):538-544.
6梁勇前,刘湘茹,胡德龙,罗蓓.二甲双胍联合西格列汀或吡格列酮对肥胖型2型糖尿病的疗效比较[J].北方药学,2015,12(5):134-135. 被引量：5
7阮勇,王秀景,谭擎缨,姚佳琦,阮芸,王静.西格列汀治疗初发2型糖尿病伴非酒精性脂肪肝的疗效及对患者血糖、血脂的影响[J].中国药师,2015,18(7):1160-1162. 被引量：40

二级参考文献45

1Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association..非酒精性脂肪性肝病诊疗指南[J].中华肝脏病杂志,2006,14(3):161-163. 被引量：1509
2中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪肝病诊疗指南.中华肝脏病杂志,2006,14(2):161-161.
3KOTRONEN A, WESTERBAEKA J, BERGHOLM R, et al. Liver fat in the metabolic syndrome [J]. Clin Endocrinol Metab , 2007, 92: 3490-3497.
4ANGULO P. Nonalcoholic fatty liver disease [J]. N Engl J Med, 2002, 346: 1221-123l.
5TARGHER G, MARRA F, MARCHESINI G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? [J] Diabetologia, 2008, 51: 1947-1953.
6SUNGKC, RYANMC, KIMBS, etal. Relationships between estimates of adiposity, insulin resistance, and nonalcoholic fatty liver disease in a large group of nondiabetic Korean adults [J]. Diabetes Care, 2007, 30: 2113-2118.
7MARCHESINI G, BRIZI M, BIANCHI G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome [J]. Diabetes, 2001, 50: 1844-1850.
8VOZAROVA B, STEFAN N, LINDSAY RS, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes [J]. Diabetes, 2002, 51:1889-1895.
9ADAMS LA, WATERS OR, KNUIMAN MW, et al. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study [J]. Am J Gastroenterol, 2009, 104:861-867.
10RYAN L, MCKIMMIE, KURT R, et al. Hepatic steatosis and subclinical cardiovascular disease in a cohort for type 2 diabetes [J]. The Diabetes Heart Study. Am J Gastroenterl, 2008, 103: 3029-3035.